Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

Stopped As the revised OHB-607-202 protocol extends the study's observational arm through 24 months corrective age (CA), the SHP607-203 protocol was terminated at 24 months CA.

Conditions

• Retinopathy of Prematurity (ROP)
• Intraventricular Hemorrhage
• Bronchopulmonary Dysplasia
• Chronic Lung Disease of Prematurity

Interventions

• OTHER: No Intervention

Sponsor

Oak Hill Bio Ltd